OlympiAD: Olaparib versus Chemotherapy in HER2-Negative Metastatic Breast Cancer and a Germline BRCA Mutation
Rita Mehta, MD of UC Irvine Health gives an overview of the OlympiAD study, which focuses on the use of olaparib in HER2 negative metastatic breast cancer. This was recorded at the 2017 MOASC Spotligh...
Author: moasc
Added: 08/02/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts